Shree Ganesh Remedies Ltd
Shree Ganesh Remedies Ltd Q1 FY27 Results & Presentation Highlights: Revenue ₹14.36 Cr, PAT ₹1.12 Cr
Q1 FY27 investor presentation: what the company reported on revenue, margins and projects.
Based on Shree Ganesh Remedies Ltd's Q1 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Q1FY27 Revenue from Operations: ₹14.36 Cr - YoY Change in Revenue: -42% - QoQ Change in Revenue: -57% - Total Income for Q1FY27: ₹15.30 Cr (down 40% YoY) - EBITDA for Q1FY27: ₹3.35 Cr (down 54% YoY) - PAT for Q1FY27: ₹1.12 Cr (down 68% YoY) - EPS for Q1FY27: ₹0.87 (down 68% YoY) Outlook: - European demand remains subdued with customers deferring orders amid geopolitical uncertainty and raw material volatility. Q1FY27 EBITDA: ₹3.35 Cr, down 54% YoY - Q1FY27 Operating Margin (EBITDA %): 23.3%, down 624 basis points YoY - Q1FY27 Profit After Tax (PAT): ₹1.12 Cr, down 68% YoY - Year-on-year changes: Revenue down 42%, EBITDA down 54%, PAT down 68% - Explicit margin outlook: No explicit margin guidance stated; management notes subdued demand and expects order volumes to restore over a couple of quarters with a meaningful improvement anticipated in H2FY27.
From Shree Ganesh Remedies Ltd's Q1 FY27 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
2 more points management made on revenue & sales performance
Profitability & Margins
See what Shree Ganesh Remedies Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Dahej Land Acquisition (2022): Acquired 40,554 sq m land for ₹11 crores for future large-scale projects; phased expansion planned; common infrastructure and warehousing under construction; multiple projects under evaluation.
- Ankleshwar Site Expansion:
- Unit 1 has 7 functional production blocks; Block 8 completed in FY25.
- Block 7 under commissioning, expected H1FY27, with projected CAPEX of ~₹20 crores (₹15 crores planned for FY26).
- Ongoing CAPEX for Plant 7 and commissioning of new Pilot Plant with automation and flow chemistry slated for Q4 FY26.
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Shree Ganesh Remedies Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
Shree Ganesh Remedies Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹33 Cr, net profit ₹6 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Shree Ganesh Remedies Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Jubilant Pharmova Ltd (Q1 FY27)
2,229 Cr., up 17% YoY (Page 97) . Key investor presentation takeaways from Jubilant Pharmova Ltd's Q1 FY27 investor presentation — and how it ranks against sect
- Beta Drugs Ltd (Q1 FY27)
Q1-FY27 revenue from operations: INR 1,255 Mn, up 25.2% YoY from INR 1,002 Mn in Q1-FY26 (Page 32). Key investor presentation takeaways from Beta Drugs Ltd's Q1
- NGL Fine Chem Ltd (Q1 FY27)
Quarterly Revenue (Q1FY27):** ₹139.16 crores . Key investor presentation takeaways from NGL Fine Chem Ltd's Q1 FY27 investor presentation — and how it ranks aga
- Anuh Pharma Ltd (Q1 FY27)
193.81 Cr, up 3.93% YoY from Rs. Key investor presentation takeaways from Anuh Pharma Ltd's Q1 FY27 investor presentation — and how it ranks against sector peer
Frequently Asked Questions
What were Shree Ganesh Remedies Ltd Q1 FY27 results?
Q1FY27 Revenue from Operations: ₹14.36 Cr - YoY Change in Revenue: -42% - QoQ Change in Revenue: -57% - Total Income for Q1FY27: ₹15.30 Cr (down 40% YoY) - EBITDA for Q1FY27: ₹3.35 Cr (down 54% YoY) - PAT for Q1FY27: ₹1.12 Cr (down 68% YoY) - EPS for Q1FY27: ₹0.87 (down 68% YoY) Outlook: - European demand remains subdued with customers deferring orders amid geopolitical uncertainty and raw material volatility. Q1FY27 EBITDA: ₹3.35 Cr, down 54% YoY - Q1FY27 Operating Margin (EBITDA %): 23.3%, down 624 basis points YoY - Q1FY27 Profit After Tax (PAT): ₹1.12 Cr, down 68% YoY - Year-on-year changes: Revenue down 42%, EBITDA down 54%, PAT down 68% - Explicit margin outlook: No explicit margin guidance stated; management notes subdued demand and expects order volumes to restore over a couple of quarters with a meaningful improvement anticipated in H2FY27.
What is Shree Ganesh Remedies Ltd share price analysis?
Shree Ganesh Remedies Ltd currently shows a neutral. The stock trades at a P/E of 58.0 with a market cap of ₹896 Cr. Investors should review the full earnings analysis for detailed insights.
Is Shree Ganesh Remedies Ltd planning capital expenditure?
Dahej Land Acquisition (2022): Acquired 40,554 sq m land for ₹11 crores for future large-scale projects; phased expansion planned; common infrastructure and warehousing under construction; multiple projects under evaluation.
Keep Shree Ganesh Remedies Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.